BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
BRISTOL MYERS SQUIBB CO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$58.83−0.92 (-1.54%)
Close on Oct 19, 2026
- Market cap
- $120.48B
- P/E (TTM)
- 13.0
- Dividend yield
- 4.23%
BRISTOL MYERS SQUIBB CO revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross product sales | $18.18B | $16.93B | $23.54B | $22.49B | $22.18B | $19.87B | $22.37B | $21.22B | $20.78B | $19.30B | $19.63B | $18.65B | 140.1% | -18.0% |
| Net product sales | $12.59B | $11.17B | $12.11B | $11.85B | $11.91B | $10.89B | $11.81B | $11.48B | $11.93B | $11.56B | $11.17B | $10.65B | 97.0% | +5.7% |
| Growth Portfolio | $7.56B | $6.23B | $7.39B | $6.86B | $6.60B | $5.56B | $6.36B | $5.81B | $5.60B | $4.79B | $5.26B | $4.95B | 58.3% | +14.6% |
| Legacy Portfolio | $5.42B | $5.28B | $5.11B | $5.37B | $5.67B | $5.64B | $5.98B | $6.08B | $6.61B | $7.07B | $6.22B | $6.02B | 41.8% | -4.4% |
| Eliquis | $4.48B | $4.14B | $3.45B | $3.75B | $3.68B | $3.57B | $3.20B | $3.00B | $3.42B | $3.72B | $2.87B | $2.71B | 34.5% | +21.8% |
| Opdivo | $2.49B | $2.15B | $2.69B | $2.53B | $2.56B | $2.27B | $2.48B | $2.36B | $2.39B | $2.08B | $2.39B | $2.28B | 19.2% | -2.9% |
| Orencia | $1.03B | $818.00M | $1.01B | $964.00M | $963.00M | $770.00M | $1.00B | $936.00M | $948.00M | $798.00M | $985.00M | $925.00M | 8.0% | +7.4% |
| Yervoy | $769.00M | $651.00M | $810.00M | $739.00M | $728.00M | $624.00M | $675.00M | $642.00M | $630.00M | $583.00M | $566.00M | $579.00M | 5.9% | +5.6% |
| Reblozyl | $735.00M | $555.00M | $666.00M | $615.00M | $568.00M | $478.00M | $547.00M | $447.00M | $425.00M | $354.00M | $320.00M | $248.00M | 5.7% | +29.4% |
| Other Growth products | $653.00M | $581.00M | $536.00M | $514.00M | $557.00M | $507.00M | $527.00M | $443.00M | $348.00M | $325.00M | $326.00M | $311.00M | 5.0% | +17.2% |
| Breyanzi | $484.00M | $411.00M | $392.00M | $359.00M | $344.00M | $263.00M | $263.00M | $224.00M | $153.00M | $107.00M | $101.00M | $92.00M | 3.7% | +40.7% |
| Revlimid | $425.00M | $349.00M | $602.00M | $575.00M | $838.00M | $936.00M | $1.34B | $1.41B | $1.35B | $1.67B | $1.45B | $1.43B | 3.3% | -49.3% |
| Camzyos | $416.00M | $314.00M | $354.00M | $296.00M | $260.00M | $159.00M | $223.00M | $156.00M | $139.00M | $84.00M | $88.00M | $68.00M | 3.2% | +60.0% |
| Alliance and other revenues | $385.00M | $321.00M | – | – | $360.00M | $315.00M | – | – | – | – | – | – | 3.0% | +6.9% |
| Opdualag | $349.00M | $295.00M | $350.00M | $299.00M | $284.00M | $252.00M | $254.00M | $233.00M | $235.00M | $206.00M | $190.00M | $166.00M | 2.7% | +22.9% |
| Other revenues | $281.00M | $227.00M | – | $247.00M | $241.00M | $227.00M | – | $304.00M | $160.00M | $172.00M | – | $183.00M | 2.2% | +16.6% |
| Opdivo Qvantig | $261.00M | $163.00M | $133.00M | $67.00M | $30.00M | $9.00M | $0 | $0 | $0 | $0 | – | – | 2.0% | +770.0% |
| Pomalyst/Imnovid | $204.00M | $513.00M | $692.00M | $675.00M | $708.00M | $658.00M | $823.00M | $898.00M | $959.00M | $865.00M | $890.00M | $872.00M | 1.6% | -71.2% |
| Other Legacy products | $170.00M | $156.00M | $199.00M | $177.00M | $223.00M | $199.00M | $250.00M | $225.00M | $222.00M | $228.00M | $231.00M | $237.00M | 1.3% | -23.8% |
| Zeposia | $169.00M | $118.00M | $159.00M | $161.00M | $150.00M | $107.00M | $158.00M | $147.00M | $151.00M | $110.00M | $133.00M | $123.00M | 1.3% | +12.7% |
| Alliance revenues | $104.00M | $94.00M | $115.00M | $125.00M | $119.00M | $88.00M | $124.00M | $105.00M | $116.00M | $134.00M | $147.00M | $138.00M | 0.8% | -12.6% |
| Sprycel | $88.00M | $73.00M | $80.00M | $119.00M | $120.00M | $175.00M | $198.00M | $290.00M | $424.00M | $374.00M | $526.00M | $517.00M | 0.7% | -26.7% |
| Sotyktu | $87.00M | $69.00M | $85.00M | $80.00M | $70.00M | $55.00M | $83.00M | $66.00M | $53.00M | $44.00M | $63.00M | $66.00M | 0.7% | +24.3% |
| Cobenfy | $63.00M | $56.00M | $50.00M | $43.00M | $35.00M | $27.00M | $10.00M | $0 | $0 | $0 | – | – | 0.5% | +80.0% |
| Abraxane | $55.00M | $50.00M | $84.00M | $74.00M | $105.00M | $105.00M | $174.00M | $253.00M | $231.00M | $217.00M | $247.00M | $260.00M | 0.4% | -47.6% |
| Krazati | $55.00M | $50.00M | $56.00M | $53.00M | $48.00M | $48.00M | $39.00M | $34.00M | $32.00M | $21.00M | $0 | $0 | 0.4% | +14.6% |
| Other revenue | -$9.00M | -$15.00M | – | – | $0 | $0 | – | – | – | – | – | – | -0.1% | – |
| Inrebic | – | – | – | – | – | – | – | – | – | – | $29.00M | $29.00M | – | – |
| Onureg | – | – | – | – | – | – | – | – | – | – | $47.00M | $43.00M | – | – |
| Abecma | – | – | $101.00M | $137.00M | $87.00M | $103.00M | $105.00M | $124.00M | $95.00M | $82.00M | $100.00M | $93.00M | – | – |
| Mature and other products | – | – | – | – | – | – | – | – | – | – | – | $476.00M | – | – |
| Total Recent LOE Products | – | – | – | – | – | – | – | – | – | – | $1.70B | $1.69B | – | – |
| In-line products and new product portfolio | – | – | – | – | – | – | – | – | – | – | $9.78B | $9.28B | – | – |
| In-line products | – | – | – | – | – | – | – | – | – | – | $8.71B | $8.35B | – | – |
| New product portfolio | – | – | – | – | – | – | – | – | – | – | $1.07B | $928.00M | – | – |
| Alliance and other revenues | – | – | – | $372.00M | $360.00M | $315.00M | – | $409.00M | $276.00M | $306.00M | – | $321.00M | – | – |
| Augtyro | – | – | – | – | – | – | $15.00M | $10.00M | $7.00M | $6.00M | $1.00M | $0 | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U S [Member] | $8.99B | $7.79B | $8.56B | $8.33B | $8.52B | $7.87B | $8.60B | $8.23B | $8.80B | $8.48B | $7.91B | $7.54B | 69.3% | +5.5% |
| International | $3.66B | $3.44B | $3.64B | $3.60B | $3.48B | $3.11B | $3.40B | $3.39B | $3.22B | – | – | – | 28.2% | +5.3% |
| Other | $318.00M | $257.00M | $309.00M | $290.00M | $270.00M | $218.00M | $350.00M | $271.00M | $176.00M | $199.00M | $184.00M | $185.00M | 2.5% | +17.8% |
| International | – | – | – | – | – | $3.11B | – | $3.39B | $3.22B | $3.19B | $3.04B | $3.24B | – | – |
From the segment and revenue-disaggregation notes of Bristol Myers Squibb's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.